We advised GSK on the transaction

Davis Polk advised GSK in connection with an extension of its existing five-year collaboration with 23andMe. 23andMe will receive a $20 million upfront payment in exchange for providing a one-year, non-exclusive license to de-identified, summary data from global genome- and phenome-wide analysis of the 23andMe database and certain research services to GSK to enable GSK to conduct drug target discovery. Any new drug discovery programs that GSK initiates during the agreement will be owned and advanced solely by GSK, and 23andMe may be eligible for downstream royalties under certain uses of the 23andMe database by GSK.

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future.

The Davis Polk IP, tech and commercial transactions team included partner David R. Bauer and counsel Samantha Lefland. All members of the Davis Polk team are based in the New York office.

Copy link to share post